NON-INSULIN THERAPIES FOR DIABETES MARKET ANALYSIS
Non-insulin Therapies for Diabetes Market: Competitive Landscape
Key players operating in the global non-insulin therapies for diabetes market include AstraZeneca, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, F. Hoffmann-La Roche Ltd., Janssen Pharmaceuticals, Merck and Company, Novartis AG, Novo Nordisk, Pfizer, Sanofi Aventis, and Takeda Pharmaceuticals.
Major players are increasingly targeting the newer class of drugs such as GLP-1 analogs or SGLT2. SGLT 2 inhibitors have been approved for use, as a treatment for diabetes since 2013. Most of the drugs under SGL2 inhibitors such as Dapagliflozin, Canagliflozin, and Empagliflozin were launched after 2013. However, intense competition in the market could make it difficult for one particular company to grab larger market share in the non-insulin therapies for diabetes market.
Non-Insulin Therapies for Diabetes Market Report Snapshots
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize NowWant to Buy a Report but have a Limited Budget?
We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail
Request Discount
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients